59107-51-6
C10H8ClN
177.63
1.289±0.06
98% min (HPLC)
93-94
Non-small-cell carcinoma
Adagrasib
5/17/2037 (Adagrasib)
KRAS G12C
10 g
ISO9001
CDMO
Availability: | |
---|---|
DESCRIPTION
With its selective inhibition of mutant KRAS G12C proteins, Adagrasib shows tremendous potential to revolutionize cancer treatment. This cutting-edge drug delivers remarkable efficacy and tolerability, offering hope to patients with limited treatment options. By adding Adagrasib to your pharmaceutical portfolio, you can contribute to the fight against KRAS G12C mutated cancers and make a meaningful impact on patients' lives.
content is empty!